Merck (MRK.US) oral new drug "Enlicizumab Tablets" has applied for listing in China.

According to the Eastmoney Financial APP, on July 9th, the official website of the CDE showed that Merck's (MRK.US) class 1 new drug "Enlic Espide" has received acceptance of its marketing application. Merck previously stated in a press release that Enlic Espide is expected to become the first approved oral PCSK9 inhibitor.